How were new medicines discovered? - PubMed (original) (raw)

Review

. 2011 Jun 24;10(7):507-19.

doi: 10.1038/nrd3480.

Affiliations

• PMID: 21701501
• DOI: 10.1038/nrd3480

Review

How were new medicines discovered?

David C Swinney et al. Nat Rev Drug Discov. 2011.

Abstract

Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.

PubMed Disclaimer

Similar articles

• The discovery of first-in-class drugs: origins and evolution.
  Eder J, Sedrani R, Wiesmann C. Eder J, et al. Nat Rev Drug Discov. 2014 Aug;13(8):577-87. doi: 10.1038/nrd4336. Epub 2014 Jul 18. Nat Rev Drug Discov. 2014. PMID: 25033734 Review.
• Phenotypic screens as a renewed approach for drug discovery.
  Zheng W, Thorne N, McKew JC. Zheng W, et al. Drug Discov Today. 2013 Nov;18(21-22):1067-73. doi: 10.1016/j.drudis.2013.07.001. Epub 2013 Jul 9. Drug Discov Today. 2013. PMID: 23850704 Free PMC article. Review.
• The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines.
  Swinney DC. Swinney DC. J Biomol Screen. 2013 Dec;18(10):1186-92. doi: 10.1177/1087057113501199. Epub 2013 Aug 27. J Biomol Screen. 2013. PMID: 23983234
• The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
  G de la Torre B, Albericio F. G de la Torre B, et al. Molecules. 2019 Feb 23;24(4):809. doi: 10.3390/molecules24040809. Molecules. 2019. PMID: 30813407 Free PMC article. Review.
• The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
  de la Torre BG, Albericio F. de la Torre BG, et al. Molecules. 2020 Feb 9;25(3):745. doi: 10.3390/molecules25030745. Molecules. 2020. PMID: 32050446 Free PMC article. Review.

Cited by

• Systems-level antimicrobial drug and drug synergy discovery.
  Roemer T, Boone C. Roemer T, et al. Nat Chem Biol. 2013 Apr;9(4):222-31. doi: 10.1038/nchembio.1205. Nat Chem Biol. 2013. PMID: 23508188
• Working memory impairment in calcineurin knock-out mice is associated with alterations in synaptic vesicle cycling and disruption of high-frequency synaptic and network activity in prefrontal cortex.
  Cottrell JR, Levenson JM, Kim SH, Gibson HE, Richardson KA, Sivula M, Li B, Ashford CJ, Heindl KA, Babcock RJ, Rose DM, Hempel CM, Wiig KA, Laeng P, Levin ME, Ryan TA, Gerber DJ. Cottrell JR, et al. J Neurosci. 2013 Jul 3;33(27):10938-49. doi: 10.1523/JNEUROSCI.5362-12.2013. J Neurosci. 2013. PMID: 23825400 Free PMC article.
• Syntheses and cell-based phenotypic screen of novel 7-amino pyrido[2,3-d]pyrimidine-6-carbonitrile derivatives as potential antiproliferative agents.
  Yang T, He H, Ang W, Yang YH, Yang JZ, Lin YN, Yang HC, Pi WY, Li ZC, Zhao YL, Luo YF, Wei Y. Yang T, et al. Molecules. 2012 Feb 24;17(3):2351-66. doi: 10.3390/molecules17032351. Molecules. 2012. PMID: 22367029 Free PMC article.
• Diagnosing the decline in pharmaceutical R&D efficiency.
  Scannell JW, Blanckley A, Boldon H, Warrington B. Scannell JW, et al. Nat Rev Drug Discov. 2012 Mar 1;11(3):191-200. doi: 10.1038/nrd3681. Nat Rev Drug Discov. 2012. PMID: 22378269 Review.
• _N_-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge.
  Hsueh SC, Luo W, Tweedie D, Kim DS, Kim YK, Hwang I, Gil JE, Han BS, Chiang YH, Selman W, Hoffer BJ, Greig NH. Hsueh SC, et al. ACS Pharmacol Transl Sci. 2021 Mar 30;4(2):980-1000. doi: 10.1021/acsptsci.1c00042. eCollection 2021 Apr 9. ACS Pharmacol Transl Sci. 2021. PMID: 33860215 Free PMC article.

References

1. 1. Expert Opin Pharmacother. 2001 Feb;2(2):351-61 - PubMed
2. 1. J Hypertens Suppl. 2006 Mar;24(1):S23-30 - PubMed
3. 1. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5 - PubMed
4. 1. Fertil Steril. 1997 Dec;68(6):967-76 - PubMed
5. 1. J Clin Invest. 2003 May;111(9):1287-95 - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information